Related Experiment Video
Updated: Dec 24, 2025
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Mesoporous silica nanoparticle-based cisplatin prodrug delivery and anticancer effect under reductive cellular
Byungjun Ahn1, Juhee Park, Kaushik Singha
1Center for Self-assembly and Complexity, Institute for Basic Science, Department of Chemistry, Polymer Research Institute, Pohang University of Science and Technology (POSTECH), Pohang, 790-784, Republic of Korea. wjkim@postech.ac.kr.
This study developed a cisplatin prodrug delivery system using mesoporous silica nanoparticles, significantly enhancing anticancer efficacy and reducing toxicity. The novel system improves drug delivery and offers a new method for real-time diagnosis.
Area of Science:
- Nanotechnology
- Materials Science
- Drug Delivery
Background:
- Cisplatin is a widely used anticancer drug but suffers from toxicity, rapid inactivation, and low efficiency.
- Developing effective drug delivery systems is crucial to overcome cisplatin's limitations.
Purpose of the Study:
- To create a prodrug delivery system for cisplatin using mesoporous silica nanoparticles.
- To enhance the anticancer effect of cisplatin while minimizing toxicity and improving drug efficiency.
Main Methods:
- Utilized fluorescent mesoporous silica nanoparticles as a template for a cisplatin prodrug.
- Attached the prodrug via a reducible linkage, enabling activation in the reductive tumor environment.
- Developed a novel, inexpensive fluorescent-based platinum quantification method.
Main Results:
- The prodrug-conjugated nanoparticles exhibited a 63-fold lower IC50 value than cisplatin in HeLa cells.
- The delivery system demonstrated enhanced cellular uptake and a potent anticancer effect.
- The new quantification method proved effective for monitoring nanoparticles.
Conclusions:
- Mesoporous silica nanoparticles effectively deliver cisplatin prodrugs, enhancing anticancer activity and reducing side effects.
- The reducible linkage ensures targeted activation of cisplatin in cancer cells.
- The fluorescent quantification method offers a viable alternative for real-time monitoring.
